EVALUATION OF THE BRONCHOPROTECTIVE EFFECT OF ARFORMOTEROL IN CHILDREN WITH

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究正在研究阿福莫特罗对运动性支气管痉挛的治疗作用。在这项研究中，我们比较了阿莫特罗吸入剂、福莫特罗粉吸入剂和安慰剂(无活性药物)。 EIB在儿童和年轻人中很常见，可以通过药物预防。FDA已批准干粉吸入器中的福莫特罗用于哮喘的维持[日常]治疗，并用于预防5岁及以上成人和儿童的EIB。福莫特罗由两种化合物组成：解释这一点的最好方法是将这两种化合物想象成你的手。福莫特罗是左右手的镜像，按在一起但只有右手活跃[R，R-福莫特罗]，左手[称为S，S-福莫特罗]在那里陪伴着它。R，R-福莫特罗又称阿莫特罗。阿福莫特罗吸入液被FDA批准用于维持治疗成人慢性阻塞性肺疾病(COPD)患者的支气管收缩。我们想知道吸入阿福莫特罗对预防EIB是否有效。这是阿福莫特罗在EIB儿童中的第三阶段研究，这意味着使用阿福莫特罗治疗EIB是实验性的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This research is studying the use of arformoterol for exercise induced bronchospasm [EIB]. In this study we compare arformoterol inhalation solution to formoterol dry powder inhaler, and placebo (no active drug). EIB is common in children and young adults and it can be prevented by using medications. Formoterol in a dry powder inhaler device has been approved by the FDA to be used in the maintenance [daily] treatment of asthma and in the prevention of EIB in adults and children 5 years of age and older. Formoterol is made of two chemical compounds: The best way to explain this is to think of these two chemical compounds as your hands. Formoterol is both the left and right hand, mirror images, pressed together but only the right hand is active [R,R-formoterol], and the left hand [called S,S-formoterol] is there keeping it company. R,R-formoterol is also called arformoterol. Arformoterol inhalation solution is approved by the FDA for maintenance treatment of bronchoconstriction in adult patients with chronic obstructive pulmonary disease [COPD]. We would like to know if arformoterol inhalation will work for the prevention of EIB. This is a Phase III study of arformoterol in children with EIB, meaning that the use of arformoterol for EIB is experimental.